Pharmaceuticals - Community Register

  

Community register of veterinary medicinal products


AUTHORISED  

Product information

Invented name: Rheumocam   
Auth. number : EU/2/07/078
Active substance : Meloxicam
ATC: Anatomical main group: QM - Musculo-skeletal system
Therapeutic subgroup: QM01 - Antiinflammatory and antirheumatic products
Pharmacological subgroup: QM01A - Antiinflammatory and antirheumatic products, non-steroids
Chemical subgroup: QM01AC - Oxicams
Chemical substance: QM01AC06 - Meloxicam
(See WHO ATCvet Index)
Indication: Rheumocam 1.5 mg/ml oral suspension for dogs:
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.

Rheumocam 1 mg chewable tablets for dogs
Rheumocam 2.5 mg chewable tablets for dogs:
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.

Rheumocam 15 mg/ml oral suspension for horses:
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.

Rheumocam 20 mg/ml solution for injection for cattle, pigs and horses:
Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.
For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.
For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

Horses:

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.
For the relief of pain associated with equine colic.

Rheumocam 5 mg/ml solution for injection for dogs and cats:
Dogs:
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

Cats:
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

Rheumocam 5 mg/ml solution for injection for cattle and pigs:
Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.
For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.
For the relief of post operative pain associated with minor soft tissue such as castration.

Rheumocam 330 mg, granules for horses.:
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses weighing between 500 and 600 kg.
Marketing Authorisation Holder: Chanelle Pharmaceuticals Manufacturing Limited
Loughrea, Co. Galway, Ireland
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
15/01/2008 Centralised - Authorisation EMEA/V/C/121 (2008)82 of 10/01/2008
20/06/2008 Centralised - Variation (no change in Commission Decision) EMEA/V/C/121/IB/1
18/08/2008 Centralised - Variation (no change in Commission Decision) EMEA/V/C/121/IB/2
20/11/2008 Centralised - Variation EMEA/V/C/121/IB/3
Updated with Decision(2009)4468 of 04/06/2009
08/06/2009 Centralised - Variation (2009)4468 of 04/06/2009
12/10/2009 Centralised - Variation EMEA/V/C/121/X/4 (2009)7885 of 08/10/2009
26/01/2011 Centralised - Variation EMEA/V/C/121/X/6 (2011)453 of 24/01/2011
18/05/2011 Centralised - Variation EMEA/V/C/121/X/7 (2011)3533 of 16/05/2011
26/01/2012 Centralised - Variation EMEA/V/C/121/X/8 (2012)484 of 24/01/2012
14/11/2012 Centralised - Variation EMEA/V/C/121/X/10 (2012)8374 of 12/11/2012
20/12/2012 Centralised - Renewal EMEA/V/C/121/R/12 (2012)9857 of 18/12/2012
15/02/2013 Centralised - Variation EMEA/V/C/121/WS/344 (2013)938 of 13/02/2013